1. Home
  2. AL vs TGTX Comparison

AL vs TGTX Comparison

Compare AL & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Air Lease Corporation

AL

Air Lease Corporation

HOLD

Current Price

$64.26

Market Cap

7.2B

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$29.73

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AL
TGTX
Founded
2010
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2B
5.5B
IPO Year
2011
1995

Fundamental Metrics

Financial Performance
Metric
AL
TGTX
Price
$64.26
$29.73
Analyst Decision
Buy
Strong Buy
Analyst Count
4
4
Target Price
$60.50
$54.75
AVG Volume (30 Days)
1.6M
1.4M
Earning Date
02-12-2026
11-03-2025
Dividend Yield
1.37%
N/A
EPS Growth
96.53
N/A
EPS
8.62
2.78
Revenue
$2,908,265,000.00
$531,898,000.00
Revenue This Year
$10.26
$87.88
Revenue Next Year
$6.10
$48.75
P/E Ratio
$7.43
$11.00
Revenue Growth
6.25
100.88
52 Week Low
$38.25
$25.28
52 Week High
$64.40
$46.48

Technical Indicators

Market Signals
Indicator
AL
TGTX
Relative Strength Index (RSI) 59.77 39.73
Support Level $64.07 $29.79
Resistance Level $64.25 $31.37
Average True Range (ATR) 0.13 0.97
MACD -0.00 -0.04
Stochastic Oscillator 69.47 8.21

Price Performance

Historical Comparison
AL
TGTX

About AL Air Lease Corporation

Air Lease Corp is an aircraft leasing company based in the United States. It is engaged in purchasing commercial jet aircrafts directly from aircraft manufacturers and leasing those aircraft to airlines throughout the world to generate attractive returns on equity. The company also sells aircraft from its fleet to third parties, including other leasing companies, financial services companies, airlines, and other investors, and offers fleet management services to investors and owners of aircraft portfolios for a management fee. Geographically, it derives a majority of its revenue from the Asia-Pacific region and the rest from Europe, Middle East and Africa, Central America, South America, Mexico, the United States, and Canada.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: